Research news
Retatrutide versus semaglutide.What TRANSCEND-T2D-2 reported.
The first Phase 3 head-to-head trial put the triple agonist against a single-receptor comparator in type 2 diabetes. Here is what the topline data showed.
PLP Research Journal
Proof Line Journal.
Research insights, tested documentation and clear comparisons.
Explore the compounds, then shop labelled vials with lab reports and Canadian shipping.
27 guides
Research news
HHS names six peptides for compounding.What the draft policy says.
A US draft policy eases enforcement for six compounded peptides, including BPC-157 and TB-500. Here is what it covers and what it leaves unchanged.
Research news
Retatrutide in Phase 3.What the TRIUMPH trials reported.
Three large trials, published in 2026, put the first triple agonist through its biggest test yet. Here is what the data showed, in plain numbers.
Documentation
Following a Canadian clinical trial: from the search portal to published results
Learn how to trace a Canadian trial from Health Canada's portal to its registry and published paper, compare outcomes, and separate trial from product authorization.
Understanding evidence
Peptide adsorption: why sample containers can change laboratory results
Understand peptide adsorption to sample containers, its limits in laboratory evidence, and the records that help distinguish calculated concentration from recovery.
Understanding evidence
Auditing a peptide claim you saw on social media
A repeatable five-step audit for tracing a peptide claim back to its evidence, with worked illustrative examples of how claims drift.
Compound guides
BPC-157: what the tendon-cell research actually reported
A plain-language guide to BPC-157 as an experimental peptide studied in tissue-repair models, and the limits of that work.
Understanding evidence
Cell studies, animal models and human trials: how to read peptide evidence
A tiering framework for peptide literature, with worked examples of what each study type can and cannot support.
Compound guides
CJC-1295 and ipamorelin: two separate signals in one blend listing
What the CJC-1295 and ipamorelin literature reports separately, and what a 10 mg blend listing leaves unspecified.
Understanding evidence
GLP-1, GIP and glucagon: understanding receptor names
What the receptor names in metabolic peptide research refer to, and why the informal GLP-3 name for retatrutide is not a receptor name.
Documentation
Peptide batch records: matching catalogue listing, vial label and laboratory report
A reusable record layout for keeping the three descriptions of the same material, listing, label and report, aligned, with unknowns recorded as unknown.
Compound guides
PT-141 (bremelanotide): melanocortin signalling and a narrow approved indication
What US bremelanotide labelling states about mechanism, indication and adverse effects, and what it excludes.
Understanding evidence
Purity, peptide content and biological activity are three different measurements
Why a purity percentage, a content figure and an activity result answer separate questions, with worked illustrative examples showing how they can disagree.
Understanding evidence
Reading a peptide study: population, comparator, endpoint and follow-up
Four questions that turn a study abstract into a sentence you can actually defend.
Compound guides
Retatrutide: three receptor targets and one 2023 phase 2 trial
What published retatrutide research reported, why it is informally called GLP-3, and why GLP-3 is not a receptor name.
Compound guides
Semaglutide: mechanism from the label, outcomes from the trial
How official labelling describes semaglutide’s GLP-1 receptor mechanism, what STEP 1 measured, and the limits of both.
Understanding evidence
Single compounds and blends: why component research is not combination evidence
How to reason about a multi-component listing when the published studies examined the components separately.
Compound guides
TB-500 and thymosin beta-4: reading the wound-repair literature carefully
What mouse wound-healing research on thymosin beta-4 shows, and why a TB-500 label needs supplier confirmation.
Compound guides
Tesamorelin: a GHRH analogue studied in a specific patient population
What the 2007 tesamorelin trial measured, why visceral fat is not general weight loss, and what that excludes.
Documentation
Understanding peptide concentration: milligrams, millilitres and sample volume
How milligrams per millilitre is calculated, how a target sample amount becomes a volume, and which assumptions the arithmetic does not make.
Documentation
Verifying a peptide COA: report number, laboratory and chain of custody
A worksheet for checking whether a certificate of analysis genuinely belongs to the vial in front of you, and what verification cannot settle.
Compound guides
Wolverine Stack: a nickname for a blend, not a molecule
How to read a BPC-157 and TB-500 blend listing when the cited research examined each component separately.
Documentation
A Canadian research buyer’s documentation checklist
A practical pre-purchase checklist for comparing research-material listings, records and identifiers.
Comparisons
Comparing peptide listings: quantity, blends and documentation
A side-by-side framework for comparing what a listing actually says before comparing price.
Storage
Planning storage for lyophilized research peptides
A documentation-first storage plan that keeps product-specific instructions in control.
Documentation
Reading a peptide COA: identity, purity and batch matching
How to read a certificate of analysis without treating one result as proof of everything.
Canada
Research materials and authorized medicines: checking Canadian product information
How to use Health Canada’s Drug Product Database without confusing an ingredient match with product authorization.
Proof Line offers by email.
For laboratory research use only. Not for human or veterinary use.